TURNOVER (x1000 NOK)
NET PROFIT (x1000 NOK)
EMPLOYEES
Leo Pharma AB
Closing information (x1000 NOK)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
168,471
|
155,556
|
149,327 |
| Financial expenses |
3,076
|
3,869
|
2,198 |
| Earnings before taxes |
5,404
|
4,253
|
5,860 |
| EBITDA |
6,532
|
6,002
|
6,192 |
| Total assets |
94,606
|
102,492
|
125,092 |
| Current assets |
90,090
|
96,161
|
117,587 |
| Current liabilities |
39,076
|
60,377
|
77,431 |
| Equity capital |
37,940
|
33,352
|
28,200 |
| - share capital |
1,031
|
1,013
|
946 |
| Employees (average) |
21
|
23
|
18 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
40.1%
|
32.5%
|
22.5% |
| Turnover per employee |
8,022
|
6,763
|
8,296 |
| Profit as a percentage of turnover |
3.2%
|
2.7%
|
3.9% |
| Return on assets (ROA) |
9.0%
|
7.9%
|
6.4% |
| Current ratio |
230.6%
|
159.3%
|
151.9% |
| Return on equity (ROE) |
14.2%
|
12.8%
|
20.8% |
| Change turnover |
10,110
|
-4,366
|
-14,665 |
| Change turnover % |
6%
|
-3%
|
-9% |
| Chg. No. of employees |
-2
|
5
|
-13 |
| Chg. No. of employees % |
-9%
|
28%
|
-42% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.